A case of malignant solitary fibrous tumor of the prostatic urethra

Tanaka, Yoshikazu; Nakamoto, Atsushi; Inada, Yuji; Narumi, Yasuo; Hirose, Yoshinobu; Azuma, Haruhito

doi:10.1259/bjrcr.20180034

Cited by 7 publications

(9 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As such, complete tumour resection with negative margins is advisable, with chemotherapy or radiotherapy reserved for non-resectable or metastatic tumours. 3,5,7 In our case, long-term control was achieved through a simple prostatectomy rather than a radical approach; however, we believe that treatment must be individualized.…”

Section: Discussionmentioning

confidence: 75%

“…2 SFT of the prostate is extremely rare with fewer than 25 cases reported in the literature to date. [3][4][5] Due to the rarity of prostatic SFT, the variation of clinical and morphological appearances of SFT, and the large number of different soft tissue tumour types, prostatic SFT remain difficult to diagnose. 6 The majority of case reports of prostatic SFTs have short-term follow-up and have been reported in men between the ages of 50 and 70.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Images – Solitary fibrous tumor of the prostate

Mishra

Corkum

Pautler³

et al. 2020

CUAJ

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 75%

Section: Introductionmentioning

confidence: 99%

Images – Solitary fibrous tumor of the prostate

Mishra

Corkum

Pautler³

et al. 2020

CUAJ

View full text Add to dashboard Cite

show abstract

“…Malignant SFTs are rare, and there are no established criteria to diagnosis malignant SFTs ( 13 ). In their study, England et al concluded the criteria for malignant SFTs ( 14 ).…”

Section: Discussionmentioning

confidence: 99%

“…Awareness of immunohistochemical and molecular biological characteristics can help to accurately diagnose SFT. Malignant SFTs are rare, and there are no established criteria to diagnosis malignant SFTs (13). In their study, England et al concluded the criteria for malignant SFTs (14).…”

Section: ) W H I C H M a K E S T H E D I A G N O S I S O F S F T C H A L L E N G I N Gmentioning

confidence: 99%

Transcatheter arterial embolization of malignant pelvic solitary fibrous tumor: case report and literature review

Yan¹,

Zheng²,

Wang³

et al. 2021

Transl Cancer Res TCR

View full text Add to dashboard Cite

Pelvic malignant solitary fibrous tumor (SFT) is a relatively rare disease, and literature on radical resection with transcatheter arterial embolization of pelvic SFT is lacking. In this work, we report on a 55-year-old man with a presacral mass who was hospitalized at our department. Computed tomography and magnetic resonance imaging indicated pelvic space-occupying lesions that were 12 cm × 10 cm in size and pelvic lesions that were not clearly demarcated from the right posterior wall of the bladder and the right ureter. This result suggested severe secondary hydronephrosis of the right renal pelvis. The patient underwent transcatheter iliac arterial embolization. Radical tumor resection was performed, and the results of pathological examination confirmed the diagnosis of malignant pelvic SFT. There was no SFT recurrence in this patient at 1-year follow-up. Herein, we report on the treatment of a patient with malignant pelvic SFT, a rare condition, who underwent successful radical resection after transcatheter arterial embolization. Transcatheter arterial embolization can block the blood supply of the SFT as much as possible and improve the possibility of tumor resection. In the future, pelvic SFTs can be considered improving the resection rate by transcatheter arterial embolization before surgery.

show abstract

“…The tumor dimensions are quite variable, ranging from 2 to 18 cm, with many reported to be > 5 cm [ 53 , 54 ]. SFTs located in the prostate may originate from the prostate or prostatic urethra [ 55 ].…”

Section: Uncommon Prostatic Diseasesmentioning

confidence: 99%

Differential diagnosis of uncommon prostate diseases: combining mpMRI and clinical information

et al. 2021

View full text Add to dashboard Cite

The differential diagnosis of abnormalities in the prostate is broad, covering common (acinar adenocarcinoma, benign prostatic hyperplasia, chronic prostatitis, hemorrhage, cysts, calcifications, atrophy and fibrosis) and less common conditions (tumors other than acinar adenocarcinoma, granulomatous prostatitis containing tuberculosis, abscesses and other conditions, and idiopathic disorders such as amyloidosis and exophytic benign prostatic hyperplasia). Recent advances in magnetic resonance imaging (MRI) of the prostate gland and imaging guidelines, such as the Prostate Imaging Reporting and Data System version 2.1 (PI-RADS v2.1), have dramatically improved the ability to distinguish common abnormalities, especially the ability to detect clinically significant prostate cancer (csPCa). Overlap can exist in the clinical history and imaging features associated with various common/uncommon prostate abnormalities, and biopsy is often required but is invasive. Prostate abnormalities can be divided into two categories: category 1, diseases for which PI-RADS scores are suitable for use, and category 2, diseases for which PI-RADS scores are unsuitable for use. Radiologists must have an intimate knowledge of other diseases, especially uncommon conditions. Past relevant history, symptoms, age, serum prostate-specific antigen (PSA) levels, MRI manifestations, and the applicability of the PI-RADS assessment should be considered when diagnosing prostate abnormalities.

show abstract

A case of malignant solitary fibrous tumor of the prostatic urethra

Cited by 7 publications

References 24 publications

Images – Solitary fibrous tumor of the prostate

Images – Solitary fibrous tumor of the prostate

Transcatheter arterial embolization of malignant pelvic solitary fibrous tumor: case report and literature review

Differential diagnosis of uncommon prostate diseases: combining mpMRI and clinical information

Contact Info

Product

Resources

About